Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or 18 F-fluorodeoxyglucose positron emission tomography/CT ( 18 F-FDG PET/CT) in patients with myeloma: Systematic review of diagnostic performance

Gariani, Joanna; Westerland, Olwen; Natas, Sarah; Verma, Hema; Cook, Gary

doi:10.1016/j.critrevonc.2018.02.012

Cited by 46 publications

(30 citation statements)

References 49 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, more sensitive imaging techniques for the diagnosis and follow-up of MM have been described, such as WBLDCT, MRI and PET/CT. Wholebody MRI and 18F-fluorodeoxyglucose-PET/CT have been described to be more accurate in detecting bone lesions in MM as compared to skeletal surveys [8][9][10][11][12][13][14], and wholebody MRI have been found to detect significantly more MM bone involvement compared to PET/CT [12]. Whole-body MRI and PET/CT are, however, limited in their availability and are relatively costly.…”

Section: Discussionmentioning

confidence: 99%

“…However, the value of conventional radiographs in detecting osteolytic lesions is limited since at least 30% of trabecular bone must be destroyed to be visible by radiograph [7]. Cross-sectional imaging techniques such as computed tomography (CT), magnetic resonance imaging (MRI) and integrated positron emission tomography/CT (PET/CT), have proven to be more accurate in detecting osteolytic and marrow replacing lesions as compared to skeletal surveys using radiographs [8][9][10][11][12][13][14]. As a result, more accurate diagnosis, staging and follow-up of MM is possible [8,9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Organ dose and total effective dose of whole-body CT in multiple myeloma patients

et al. 2019

View full text Add to dashboard Cite

Objective To evaluate organ dose and total effective dose of whole-body low-dose CT (WBLDCT) performed on different CTscanner models in patients with multiple myeloma (MM) and to compare it to the effective dose of radiographic skeletal survey and representative diagnostic CTs. Material and methods We retrospectively analyzed data from 228 patients (47.4% females, mean age 67.9 ± 10.4 years, mean weight 81.8 ± 22.4 kg) who underwent WBLDCT for the work-up or surveillance of MM. Patients were scanned using one of six multi-detector CT-scanners. Organ doses and total effective doses per scan were calculated using a commercially available dosemanagement platform (Radimetrics, Bayer Healthcare, Leverkusen, Germany). The median effective dose was compared to radiographic skeletal survey and representative diagnostic CTs. Results The mean effective dose of our WBLDCT-protocol was 4.82 mSv. A significantly higher effective dose was observed in females compared to males (4.95 vs. 4.70 mSv, P = 0.002). Mean organ dose ranged from 3.72 mSv (esophagus) to 13.09 mSv (skeleton). Mean effective dose varied amongst different CT-scanners (range 4.34-8.37 mSv). The median effective dose of WBLDCT was more than twice the dose of a skeletal survey (4.82 vs. 2.04 mSv), 23% higher than a diagnostic contrast-enhanced chest CT (3.9 mSv), 46% lower than a diagnostic contrast-enhanced abdomen/pelvis CT (9.0 mSv), and 45% lower than a lumbar spine CT (8.7 mSv). Conclusions WBLDCT in MM has a higher effective dose than a radiographic skeletal survey, but a lower effective dose than diagnostic CTs of lumbar spine, abdomen and pelvis. This underlines the broad applicability of WBLDCT in the management of MM patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Organ dose and total effective dose of whole-body CT in multiple myeloma patients

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A recent systematic review compared whole-body MRI and FDG PET/CT in their ability to detect myeloma skeletal lesions and suggested that MRI is more sensitive but less specific than FDG PET/CT. Yet, it also concluded that most of the included studies were heterogeneous and lacking an independent reference standard [47].…”

Section: The Evolving Role Of Fdg-pet/ct In Multiple Myelomamentioning

confidence: 99%

Multiple Myeloma Associated Bone Disease

Rasch

Lund

Asmussen

et al. 2020

Cancers

View full text Add to dashboard Cite

The lytic bone disease is a hallmark of multiple myeloma, being present in about 80% of patients with newly diagnosed MM, and in more during the disease course. The myeloma associated bone disease (MBD) severely affects the morbidity and quality of life of the patients. MBD defines treatment demanding MM. In recent years, knowledge of the underlying pathophysiology has increased, and novel imaging technologies, medical and non-pharmaceutical treatments have improved. In this review, we highlight the major achievements in understanding, diagnosing and treating MBD. For diagnosing MBD, low-dose whole-body CT is now recommended over conventional skeletal survey, but also more advanced functional imaging modalities, such as diffusion-weighted MRI and PET/CT are increasingly important in the assessment and monitoring of MBD. Bisphosphonates have, for many years, played a key role in management of MBD, but denosumab is now an alternative to bisphosphonates, especially in patients with renal impairment. Radiotherapy is used for uncontrolled pain, for impeding fractures and in treatment of impeding or symptomatic spinal cord compression. Cement augmentation has been shown to reduce pain from vertebral compression fractures. Cautious exercise programs are safe and feasible and may have the potential to improve the status of patients with MM.

show abstract

“…While the guidelines state that [ 18 F]FDG‐PET/CT should be considered the preferred imaging technique to evaluate and monitor metabolic response to therapy in MM, there are presently no studies that directly compare [ 18 F]FDG‐PET/CT with WB‐DWI or DCE‐MRI. A recent systematic review concluded that data on this topic are too heterogeneous, with biased accrual, and lack an independent reference standard, which also precluded a meta‐analysis . Therefore, it remains unclear which test may be best for response assessment.…”

Section: Myelomamentioning

confidence: 99%

MRI and PET/MRI in hematologic malignancies

Mayerhoefer

Archibald

Messiou

et al. 2019

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or 18 F-fluorodeoxyglucose positron emission tomography/CT ( 18 F-FDG PET/CT) in patients with myeloma: Systematic review of diagnostic performance

Abstract: Studies were heterogeneous, the majority lacking an independent reference standard. Future prospective trials should address these limitations and assess the impact of WBMRI on management.

Cited by 46 publications

References 49 publications

Organ dose and total effective dose of whole-body CT in multiple myeloma patients

Organ dose and total effective dose of whole-body CT in multiple myeloma patients

Multiple Myeloma Associated Bone Disease

MRI and PET/MRI in hematologic malignancies

Contact Info

Product

Resources

About